Global Emergence of Resistance to Fluconazole and Voriconazole in Candida parapsilosis in Tertiary Hospitals in Spain During the C OVID-19 Pandemic
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Background: Candida parapsilosis is a frequent cause of candidemia worldwide. Its incidence is associated with the use of medical implants, such as central venous catheters or parenteral nutrition. This species has reduced susceptibility to echinocandins, and it is susceptible to polyenes and azoles. Multiple outbreaks caused by fluconazole-nonsusceptible strains have been reported recently. A similar trend has been observed among the C. parapsilosis isolates received in the last 2 years at the Spanish Mycology Reference Laboratory. Methods: Yeast were identified by molecular biology, and antifungal susceptibility testing was performed using the European Committee on Antimicrobial Susceptibility Testing protocol. The ERG11 gene was sequenced to identify resistance mechanisms, and strain typing was carried out by microsatellite analysis. Results: We examined the susceptibility profile of 1315 C. parapsilosis isolates available at our reference laboratory between 2000 and 2021, noticing an increase in the number of isolates with acquired resistance to fluconazole, and voriconazole has increased in at least 8 different Spanish hospitals in 2020–2021. From 121 recorded clones, 3 were identified as the most prevalent in Spain (clone 10 in Catalonia and clone 96 in Castilla-Leon and Madrid, whereas clone 67 was found in 2 geographically unrelated regions, Cantabria and the Balearic Islands). Conclusions: Our data suggest that concurrently with the coronavirus disease 2019 pandemic, a selection of fluconazole-resistant C. parapsilosis isolates has occurred in Spain, and the expansion of specific clones has been noted across centers. Further research is needed to determine the factors that underlie the successful expansion of these clones and their potential genetic relatedness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.64,119”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [119]
The cited source says what the claim attributes to it.
In the citing paper
“However, fluconazole resistance has emerged over the last decade and over 50% of C. parapsilosis isolates are resistant in some series.64,119”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PCR protocols — A guide to methods and applications
U.G. (1990) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(90)90252-7 · Cited by 11,702
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Changes in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
Bartoletti, M., Pascale, R., Cricca, M., Rinaldi, M., Maccaro, A., Bussini, L., Fornaro, G., Tonetti, T., Pizzilli, G., Francalanci, E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1065 · Cited by 473
Candida parapsilosis: from genes to the bedside
Tóth, R., Nosek, J., Mora-Montes, H. M., Gabaldon, T., Bliss, J. M., Nosanchuk, J. D., Turner, S. A., Butler, G., Vágvölgyi, C., & Gácser, A. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00111-18 · Cited by 327
Puig-Asensio, M., Padilla, B., Garnacho-Montero, J., Zaragoza, O., Aguado, J. M., Zaragoza, R., Montejo, M., Muñoz, P., Ruiz-Camps, I., Cuenca-Estrella, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12380 · Cited by 299 · cited 2×
“associated to a higher risk of infection [5, 6].”
BackgroundResultSelf-citationArastehfar, A., Carvalho, A., Nguyen, M. H., Hedayati, M. T., Netea, M. G., Perlin, D. S., & Hoenigl, M. (2020) · Journal of Fungi · doi:10.3390/jof6040211 · Cited by 272 · cited 1×
“diseases, such as COVID-associated pulmonary aspergillosis (CAPA) [36–38], mucormycosis [39–41], and Candida infections [42, 43] (see reviews in [44, 45]).”
BackgroundCOVID-19-associated opportunistic infections: a snapshot on the current reports
Abdoli, A., Falahi, S., & Kenarkoohi, A. (2021) · Clinical and Experimental Medicine · doi:10.1007/s10238-021-00751-7 · Cited by 184 · cited 1×
“11 Pulmonary Aspergillosis (CAPA) [35-37], mucormycosis [38-40] and Candida 352 infections [41, 42] (see reviews in [43, 44]).”
BackgroundPeman, J., Canton, E., Quindos, G., Eraso, E., Alcoba, J., Guinea, J., Merino, P., Ruiz-Perez-de-Pipaon, M. T., Perez-del-Molino, L., Linares-Sicilia, M. J., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks019 · Cited by 159 · cited 1×
“the several former epidemiological studies that have been carried out in Spain 313 [6, 7, 30, 31], suggesting a new and worrisome change in the epidemiological 314 incidence of FNS C.”
ResultSelf-citationCantón, E., Pemán, J., Quindós, G., Eraso, E., Miranda-Zapico, I., Álvarez, M., Merino, P., Campos-Herrero, I., Marco, F., de la Pedrosa, E. G. G., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00466-11 · Cited by 157 · cited 1×
“the several former epidemiological studies that have been carried out in Spain 313 [6, 7, 30, 31], suggesting a new and worrisome change in the epidemiological 314 incidence of FNS C.”
Result
Cited by
Daneshnia, F., de Almeida Júnior, J. N., Ilkit, M., Lombardi, L., Perry, A. M., Gao, M., Nobile, C. J., Egger, M., Perlin, D. S., Zhai, B., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00067-8 · Cited by 257
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Giannella, M., Lanternier, F., Dellière, S., Groll, A. H., Mueller, N. J., Alastruey‐Izquierdo, A., & Slavin, M. A. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.08.006 · Cited by 106
Candida parapsilosis complex in the clinical setting
Govrins, M. A., & Lass‐Flörl, C. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00961-8 · Cited by 94
“Homozygous mutations cause higher minimal inhibitory concentrations (MICs) than heterozygous ones 150 ; usually, strains with the above-mentioned substitutions are susceptible to amphotericin B and echinocandins including ibrexafungerp.”
BackgroundFluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
“…et al., 2021; Fekkar et al., 2021; Thomaz et al., 2021; Alcoceba et al., 2022, Diaz-Garcia et al., 2022a, Hare et al., 2022; Thomaz et al., 2022; Zaragoza et al., 2022) K143R** R S (Singh et al., 2019, Arastehfar et al., 2020a, Castanheira et al., 2020) G458S*** R R or I (Arastehfar et al.,…”
Self-citationZhai, B., Liao, C., Jaggavarapu, S., Tang, Y., Rolling, T., Ning, Y., Sun, T., Bergin, S. A., Gjonbalaj, M., Miranda, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03183-4 · Cited by 62
Brassington, P. J. T., Klefisch, F.-R., Graf, B., Pfüller, R., Kurzai, O., Walther, G., & Barber, A. E. (2024) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.07.012 · Cited by 42
Siopi, M., Georgiou, P., Paranos, P., Beredaki, M.-I., Tarpatzi, A., Kalogeropoulou, E., Damianidou, S., Vasilakopoulou, A., Karakosta, P., Pournaras, S., et al. (2024) · Eurosurveillance · doi:10.2807/1560-7917.es.2024.29.29.2300661 · Cited by 39
“The spread of increase in the incidence of fluconazole-resistant C. parapsilosis SC during the COVID-19 era has not been driven by the selective pressure of fluconazole and voriconazole consumption, as previously described [33].”
ResultFranconi, I., Rizzato, C., Tavanti, A., Falcone, M., & Lupetti, A. (2023) · Journal of Fungi · doi:10.3390/jof9101012 · Cited by 35
Treatment of invasive candidiasis in the era of Candida resistance
Paiva, J.-A., & Pereira, J. M. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001077 · Cited by 35
Vena, A., Tiseo, G., Falcone, M., Bartalucci, C., Marelli, C., Cesaretti, M., Pilato, V. D., Escribano, P., Forniti, A., Giacobbe, D. R., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae603 · Cited by 28
Self-citationRamos, L. S., Barbosa, P. F., Lorentino, C. M. A., Lima, J. C., Braga, A. L., Lima, R., Giovanini, L., Casemiro, A. L., Siqueira, N. L. M., da Costa, S. C., et al. (2025) · Current Research in Microbial Sciences · doi:10.1016/j.crmicr.2025.100354 · Cited by 33
Severe Candida infections in critically ill patients with COVID-19
Koulenti, D., Karvouniaris, M., Paramythiotou, E., Koliakos, N. N., Μάρκου, Ν., Paranos, P., Meletiadis, J., & Blot, S. I. (2023) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.07.005 · Cited by 26
“[ 55 ] The expansion of various clones around the country was responsible for resistance selection.”
BackgroundResultInfluentialMcTaggart, L. R., Eshaghi, A., Hota, S. S., Poutanen, S. M., Johnstone, J., Luca, D. G. D., Bharat, A., Patel, S. N., & Kus, J. V. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.01161-23 · Cited by 25
Misas, E., Witt, L. S., Farley, M. M., Thomas, S., Jenkins, E. N., Gade, L., Peterson, J. G., Restrepo, A. M., Fridkin, S. K., Lockhart, S. R., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae264 · Cited by 24
Hartuis, S., Ourliac‐Garnier, I., Robert, E., Albassier, M., Duchesne, L., Beaufils, C., Kuhn, J., Pape, P. L., & Morio, F. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00022-24 · Cited by 26
The challenges of the genome-based identification of antifungal resistance in the clinical routine
Alastruey‐Izquierdo, A., & Martín-Galiano, A. J. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1134755 · Cited by 20
“, 2020) and the emergence of fluconazole resistant Candida parapsilosis besides its intrinsic higher MICs to echinocandins (Trevijano-Contador et al., 2022).”
BackgroundWon, E. J., Sung, H., & Kim, M. (2024) · Journal of Fungi · doi:10.3390/jof10030193 · Cited by 19
Araujo, J. M., de Almeida, J. N., Magri, M. M. C., Costa, S. F., & Guimarães, T. (2024) · Journal of Fungi · doi:10.3390/jof10040268 · Cited by 18
Fungal Infections in the ICU during the COVID-19 Pandemic in Mexico
Román-Montes, C. M., Bojorges-Aguilar, S., Corral-Herrera, E. A., Rangel‐Cordero, A., Diaz‐Lomelí, P., Sánchez, A. C., Martínez-Guerra, B. A., Rajme‐López, S., Tamez-Torres, K. M., Martínez‐Gamboa, R. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050583 · Cited by 17
Mesquida, A., Alcoceba, E., Padilla, E., Ramírez, A., Merino, P., González‐Romo, F., Carolis, E. D., Sanguinetti, M., Mantecón‐Vallejo, M. D. L. Á., Muñoz‐Algarra, M., et al. (2024) · Mycoses · doi:10.1111/myc.13706 · Cited by 17
Self-citationDutra, M. D. S., Araújo, P. R. M., da Rocha, M. G., Pereira, V. C., Freitas, A. S., Lopes, R. G. P., Souza, P. F. N., Montenegro, R. C., Pereira‐Neto, W. D. A., Araújo, G. D. S., et al. (2025) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001976 · Cited by 13
“In addition, in the same period, an increase in the frequency of C. parapsilosis isolates resistant to fluconazole has also been observed [9–11].”
McHugh, J., Chesdachai, S., Dunsirn, M., Wengenack, N. L., & Vergidis, P. I. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf249 · Cited by 12
Semet, C., Kazak, E., Ener, B., Aksoy, S. A., Özkaya, G., Ağca, H., Heper, Y., Yılmaz, E., & Akalın, H. (2025) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-025-01559-w · Cited by 10
“This rise is believed to be significantly influenced by global and regional outbreaks, as well as the pharmacological pressures applied during treatment [27, 28].”
Marzucco, A., Gatti, G., Montanari, M. S., Fantini, M., Colosimo, C., Tamburini, M. V., Arfilli, V., Morotti, M., Schiavone, P., Congestrì, F., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12010153 · Cited by 11
Lin, G.-L., Chang, P.-H., Lee, I., Chen, Y., & Lee, C. (2024) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2024.07.014 · Cited by 9
Fungal burden assessment in hospital zones with different protection degrees
García-Gutiérrez, L., Rojas, B. B., de Pipaón, M. R.-P., Egido, S. H., Gaitán, A. C. R., Laiz, L., Pemán, J., Cuétara-García, M. S., Mellado, E., & Martin-Sanchez, P. M. (2024) · Building and Environment · doi:10.1016/j.buildenv.2024.112454 · Cited by 9
Clinical impact of fluconazole-resistant Candida parapsilosis : a narrative review
Bartalucci, C., Vena, A., Giacobbe, D. R., & Bassetti, M. (2025) · Future Microbiology · doi:10.1080/17460913.2025.2544443 · Cited by 9
Torres-Cano, A., de Armentia, C., Roldán, A., López‐Peralta, E., Manosalva, J., Amador, P. M., González‐Romo, F., Puig‐Asensio, M., Ardanuy, C., Martín-Gómez, M. T., et al. (2025) · Journal of Fungi · doi:10.3390/jof11040299 · Cited by 5
Self-citationPalladini, G., Lepera, V., Trubini, S., Tocci, G., Zappavigna, A., Iskandar, E. N., Ferrari, G., Prigitano, A., Ferraro, N., Schiavo, R., et al. (2025) · Mycoses · doi:10.1111/myc.70111 · Cited by 6
“In Europe, the clonal dissemination of fluconazole-resistant C. parapsilosis affected many hospitals in Spain, France, Greece and Italy [19, 26, 39–46].”
Baba, H., Kanamori, H., Nakayama, A., Sato, T., Katsumi, M., Chida, T., Ikeda, S., Seki, R., Arai, T., Kamei, K., et al. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.77 · Cited by 6
Contribution of DNA Metabarcoding to the Environmental Fungal Assessments in Hospitals
García-Gutiérrez, L., Mellado, E., & Martin-Sanchez, P. M. (2025) · Microbial Ecology · doi:10.1007/s00248-025-02626-w · Cited by 4
Wang, Y., Hsu, J., Lee, W.-J., WANG, S., Chu, S., Huang, H., Yang, P., Fu, R.-H., & Tsai, M.-H. (2023) · Microorganisms · doi:10.3390/microorganisms11051149 · Cited by 4
“parapsilosis BSIs has been reported, which may pose a therapeutic challenge to clinicians [17,18].”
BackgroundThe S862C amino acid change in CpMrr1 confers fluconazole resistance in Candida parapsilosis
Franconi, I., Poma, N. V., Rizzato, C., Maltinti, L., Falcone, M., Tavanti, A., & Lupetti, A. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf051 · Cited by 4
Ngo, T. M. C., That, D. D. T., Nu, P. A. T., Cao, L. C., Giang, T. T., Thao, T. B., Ha, T. N. T., Minh, T. V., Nguyen, P. V., Mai, B. H. A., et al. (2025) · Medical Mycology · doi:10.1093/mmy/myaf064 · Cited by 3
Current Perspectives on Antifungal Resistance: Focus on Opportunistic Mycoses
Muñoz, N. R. A., & Flores, C. F. Y. (2024) · Salud Ciencia y Tecnología · doi:10.56294/saludcyt20241064 · Cited by 3
Atalay, S., Çağlayan, D., Arkalı, E., Sönmez, U., & Şamlıoğlu, P. (2024) · Mycoses · doi:10.1111/myc.13717 · Cited by 3
Won, E. J., Sung, H., & Kim, M. (2024) · Journal of Fungi · doi:10.3390/jof10090624 · Cited by 3
“Although C. parapsilosis is typically considered susceptible to azole antifungals, recent reports indicate an increasing incidence of fluconazole-resistant (FR) C. parapsilosis BSIs in several countries [13–15].”
BackgroundOñate-Gutiérrez, J. M., Álvarez, C., Cañadas-Aragón, C. P., & Vergara, H. (2026) · Journal of Fungi · doi:10.3390/jof12040278 · Cited by 3
“The C. parapsilosis complex demonstrated a sustained increase in fluconazole resistance, while C. auris has been reported to have an ICU prevalence of 1.22%, characterized by high nosocomial transmissibility, environmental persistence, and intrinsic multidrug resistance [16,17].”
InfluentialMachine learning-based drug susceptibility prediction from Candida genomic data
Wei, Z., Li, S., Wang, S. X., Wang, Q., Wang, Z., & Wang, H. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2026.107910 · Cited by 2
Trevijano‐Contador, N., López‐Peralta, E., López‐López, J., Roldán, A., de Armentia, C., & Zaragoza, Ó. (2024) · Mycoses · doi:10.1111/myc.13811 · Cited by 2
“Additionally, isolates carrying the Erg11 G458S mutation have been detected although with lower incidence [25, 27].”
InfluentialSelf-citationInter‐Institutional Dynamics and Impact of Fluconazole‐Resistant Candida parapsilosis
Korem, M., Reich, S., Rahav, G., Yahav, D., Weinberger, M., Novikov, A., Mizrahi, N., & Ben‐Ami, R. (2025) · Mycoses · doi:10.1111/myc.70017 · Cited by 2
Candida parapsilosis resistente a azoles en Unidades de Críticos
Antona-Urieta, N., Andrés, J. L. B., Seijas, I., Lucas, J. H., Boado-Varela, V., López‐Peralta, E., Alcázar‐Fuoli, L., Zaragoza, Ó., & López-Soria, L. (2025) · Revista Española de Quimioterapia · doi:10.37201/req/122.2024 · Cited by 1
Self-citationFekkar, A., Blaize, M., Cassaing, S., Sendid, B., Pasquier, G., Imbert, S., Hennequin, C., Botterel, F., Morio, F., Ménotti, J., et al. (2026) · New Microbes and New Infections · doi:10.1016/j.nmni.2026.101738 · Cited by 1
“For several years now, a global phenomenon has emerged with the wide-spread of fluconazole-resistant C. parapsilosis isolates, often responsible for epidemics in hospitals, particularly in intensive care units [4 – 7].”
Vumbaca, M., Biffignandi, G. B., Cavanna, C., Bellinzona, G., Corbella, M., Mileto, I., Rhodes, J. L., Corander, J., Baldanti, F., & Sassera, D. (2026) · Mycopathologia · doi:10.1007/s11046-026-01070-9 · Cited by 1
Doorley, L. A. (2023) · doi:10.21007/etd.cghs.2023.0620 · Cited by 1
Nunez‐Rodriguez, J. C., Biriukov, V. V., Redondo-Río, Á., Parmar, M., Schikora-Tamarit, M. À., Ahaik, I., del Olmo, V., & Gabaldón, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.19.725100 · Cited by 2
C. parapsilosis: The importance of an emerging pathogen
Martín-Gómez, M. T., & Puig‐Asensio, M. (2022) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2022.09.005
Self-citationC. parapsilosis: The importance of an emerging pathogen
Martín-Gómez, M. T., & Puig‐Asensio, M. (2023) · Enfermedades infecciosas y microbiologia clinica (English ed ) · doi:10.1016/j.eimce.2022.09.010
Self-citationResistant fungal infection: a matter of importance not only in critical COVID patients
Seijas, I., Lucas, J. H., Andrés, J. L. B., Soria, L. M. L., & Boado, V. (2023) · Minerva Anestesiologica · doi:10.23736/s0375-9393.23.17681-4
Araujo, J. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2023.tde-05022024-163245
Characterization of COVID ‐19‐Associated Candidemia Among Burn Patients
Salimi, M., Javidnia, J., Moslemi, A., Abastabar, M., Mobayen, M., Rahimzadeh, G., Tirabadi, N. M., Nouranibaladezaei, S., Asghari, H., Sobouti, B., et al. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70031
“Studies in Canada [22] and Spain [23, 42] reported resistance to fluconazole, which was consistent with our findings.”
Masfiyah, M., Rahayu, R., & Mujayanto, R. (2025) · Journal of Advanced Multidisciplinary Research · doi:10.30659/jamr.6.1.89-95
Epidemiological assessment and risk factors for mortality of bloodstream infections by Candida sp
Araujo, J. M. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Namysł, M., Skóra, M., Pomorska-Wesołowska, M., Romanik, M. K., Kwapniewska, W. Ś. –., Serwacki, P., Pawłowska, I., Olechowska‐Jarząb, A., & Wójkowska‐Mach, J. (2026) · Journal of Fungi · doi:10.3390/jof12030212
Pinheiro, D. O. B. P., Castiñeiras, A. C., Guimarães, L. F., Barreiros, G., Rocha, H. L. R., Nucci, M., & Nouér, S. A. (2026) · Medical Mycology · doi:10.1093/mmy/myag079
Rodrigues, L. S., Barbosa, S. D. C., Chacon, A. P. S., Siqueira, A. C., Bernardi, G., Pillonetto, M., Vicente, V. A., Arend, L. N. V. S., Svidzinski, T. I. E., & Dalla-Costa, L. M. (2026) · Mycopathologia · doi:10.1007/s11046-026-01095-0
“…not been previously described, it is located within the C-terminal activation domain, a known hotspot for gain-of-function mutations in this transcription factor; such mutations can result in the constitutive hyperactivation of efflux pumps, such as Mdr1p and Cdr1p, leading to resistance [28, 29].”
López‐Peralta, E., de Armentia, C., Roldán, A., Sánchez-Galiano, S., de Pipaón, M. R. P., Velasco, I. M., Lomba, M. L., Durán-Valle, M. T., Amador, P. M., González‐Romo, F., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.740302
Self-citationJones, M. N., Nigo, M., Pérez, M. E., Casarin, S., Sanghvi, A., Jones, S. L., Corry, D. B., Arias, C. A., & Adelman, M. W. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag558
Metadata
- Authors
- Trevijano-Contador, N., Torres-Cano, A., Carballo-González, C., Puig-Asensio, M., Martín-Gómez, M. T., Jiménez-Martínez, E., Romero, D., Nuvials, F. X., Olmos-Arenas, R., Moretó-Castellsagué, M. C., Fernández-Delgado, L., Rodríguez-Sevilla, G., Aguilar-Sánchez, M.-M., Ayats-Ardite, J., Ardanuy-Tisaire, C., Sanchez-Romero, I., Muñoz-Algarra, M., Merino-Amador, P., González-Romo, F., Megías-Lobón, G., García-Campos, J. A., Mantecón-Vallejo, M. Á., Alcoceba, E., Escribano, P., Guinea, J., Durán-Valle, M. T., Fraile-Torres, A. M., Roiz-Mesones, M. P., Lara-Plaza, I., de Ayala, A. P., Simón-Sacristán, M., Collazos-Blanco, A., Nebreda-Mayoral, T., March-Roselló, G., Alcázar-Fuoli, L., & Zaragoza, O.
- Affiliations
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III. Carretera Majadahonda-Pozuelo , Madrid , Spain
- Instituto de Salud Carlos III (ES)
- Department of Infectious Diseases, Hospital Universitari de Bellvitge-Institut d´Investigació Biomèdica de Bellvitge (IDIBELL) , Barcelona , Spain
- Universitat Autònoma de Barcelona (ES)
- Department of Microbiology, Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona , Barcelona , Spain
- Intensive Care Unit, Vall D'Hebron University Hospital, Universitat Autònoma de Barcelona , Barcelona , Spain
- Bellvitge University Hospital (ES)
- Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL , Barcelona , Spain
- Microbiology Department, Hospital Universitario Puerta de Hierro , Majadahonda, Madrid , Spain
- Microbiology Department, Hospital Universitario Clínico San Carlos , Madrid , Spain
- Department of Clinical Microbiology, Hospital Universitario de Burgos , Burgos, Castilla y León , Spain
- Hospital Universitario de Burgos (ES)
- Hospital Universitario Son Espases (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
- Microbiology and Parasitology Department, Hospital Universitario de Móstoles , Madrid , Spain
- Microbiology Department, Marqués de Valdecilla Universitary Hospital and Instituto de Investigación Valdecilla (IDIVAL), Santander, Cantabria, Spain
- Marqués de Valdecilla University Hospital (ES)
- Microbiology Unit, Universitary Hospital 12 de Octubre , Madrid , Spain
- Microbiology and Parasitology Department, Hospital Central de la Defensa Gómez Ulla , Madrid , Spain
- Hospital Clínico Universitario de Valladolid (ES)
- ORCID
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-11-01
- Volume
- 9
- Issue
- 11
- Pages
- ofac605-ofac605
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC9709632
- OpenAlex
- W4308458455
- Cited by
- 54
- References
- 47
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 18 · 2023: 12 · 2022: 2
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc-nd)
- Funders
- National Centre for Microbiology
- Instituto de Salud Carlos III
- Center for Biomedical Research (CB21/13/00105, CB21/13/00009, CB06/06/0037, CB06/06/0058)
- Fondo de Investigación (MPY 117/18, MPY 305/20)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Yeasts and Rust Fungi Studies
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Keywords
- Candida parapsilosis, fluconazole resistance, voriconazole resistance, azole resistance, candidemia, ERG11, molecular epidemiology, COVID-19 pandemic, antifungal susceptibility, Spain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.